A study questions the safety of pregabalin during pregnancy
Treatment with pregabalin (Lyrica® or generica) in pregnant women could put the fetus at serious risk. A study led by the STIS and published in Neurology found an increased frequency of major malformations following exposure to pregabalin during the first trimester of pregnancy.
VALPROATE: NEW MEASURES AIMED TO LIMIT EXPOSURE DURING PREGNANCY AND TO INFORM HEALTH PROFESSIONALS AND PATIENTS
PARACETAMOL REMAINS THE ANALGESIC OF CHOICE DURING PREGNANCY
Text available in French
LE PARACETAMOL RESTE L'ANTALGIQUE DE 1er CHOIX PENDANT LA GROSSESSE
Deux études épidémiologiques scandinaves sèment le doute sur la sécurité d'emploi du paracétamol pendant la grossesse. L'interprétation alarmiste des résultats, véhiculée dans les médias ces dernières semaines, demande à rappeler que le paracétamol reste l'antalgique de palier I de premier choix pendant la grossesse en raison de son profil de sécurité favorable bien établi.
TOPIRAMATE AND RISK OF CLEFT LIP OR PALATE
FDA issues a warning about the risk of cleft lip or cleft palate after exposure to topiramate (Topamax® and generics) during early pregnancy.
INFLUENZA A H1N1 FLU: ANTIVIRAL DRUGS AND VACCINES
The Swiss Teratogen Information Service (STIS) commits itself to the follow-up of prospective exposures to antiviral treatments and the Celtura® vaccine.
MYCOPHENOLATE MOFETIL/MYCOPHENOLATE SODIUM AND CONGENITAL MALFORMATION
The FDA has issued an alert regarding mycophenolate mofetil (MFM, CellCept®) and mycophenolate sodium (Myfortic®) following reports on outcomes of pregnancies suggesting an increased risk of pregnancy loss and congenital malformation in association with maternal use of these drugs during pregnancy. Mycophenolate mofetil and mycophenolate sodium must be considered as associated with an increased risk of pregnancy loss and congenital malformation with regards to attitudes of prescription and information to patients.
NSAIDS AND PREGNANCY: NEW ELEMENTS TO PREFER PARACETAMOL
Two studies suggest an increased risk of miscarriage after nonsteroidal anti-inflammatory drugs (NSAID) use during the first trimester of pregnancy. The NSAID exposure during the first trimester of pregnancy could also be related to an increased risk in congenital anomalies (specifically cardiac defects). However, this teratogenic potential remains uncertain. In practice, a benefit/risk evaluation on a case-by-case basis should always be undertaken before prescribing NSAIDs during the first trimester of pregnancy and paracetamol should, whenever possible, be used instead.
ASSOCIATION OF LAMOTRIGINE WITH AN INCREASED RISK OF NON-SYNDROMIC ORAL CLEFTS
New data from the North American Antiepilectic Drug Pregnancy Registry (NAAED) suggest a possible association between exposure to lamotrigine monotherapy during the first trimester of pregnancy and cleft lip and/or cleft palate.
ACEI COULD BE ASSOCIATED WITH AN INCREASED RISK OF CONGENITAL MALFORMATIONS
Exposure to ACEI during the first trimester of pregnancy could be associated with an increase in the risk of congenital anomalies among newborns.
© Swiss Teratogen Information Service 2016 - All rights reserved.
Last update: 30.6.2016